Web8 sep. 2024 · MeMed Diagnostics, a Haifa-based firm that develops diagnostic solutions to monitor the body’s immune state, said it will partner with Italian diagnostic firm DiaSorin to commercialize a test... WebEuropean Commission Choose your language Choisir une langue ...
MeMed to predict which COVID-19 patients will worsen - Globes
Web20 sep. 2024 · The test is designed to indicate whether a person is suffering from a bacterial or viral infection within 15 minutes. Chloe Kent Credit: Shutterstock The US Food and Drug Administration (FDA) has approved a test developed by Israeli medtech firm MeMed that can rapidly determine whether an infection has been caused by a bacteria or a virus. Web22 sep. 2024 · The test runs on the MeMed Key immunoassay platform that enables the measurement of multiple proteins without having to send samples to a remote laboratory for analysis. The “point-of-need” test … bomba warren 3830
MeMed Company Profile: Valuation & Investors PitchBook
Web2015. MeMed awarded €3M from the European Commission to fund the Respiratory-ImmunoDx project, after achieving top place out of 89 competitive applicants. Respiratory-ImmunoDx is a three year research program funded by the European Commission through the Horizon 2024’s Small and Medium-sized Enterprise (SME) instrument. WebMeMed University of Connecticut About Service and Operations leadership in the medical diagnostic space with international experience. A biomedical engineer by heart, always interested to expand... Web24 dec. 2024 · December 30, 2024 updated by: MeMed Diagnostics Ltd. Prospective, Multi-Center, Observational, Blinded Study to Establish the Diagnostic Performance of the MeMed BV™ Test for Differentiating Bacterial From Viral Infection in Patients With Suspected Acute Bacterial or Viral Infection ("APOLLO" STUDY) gmg hotel coron